Pamorelin LA 3.75 mg

Pamorelin LA 3.75 mg is a medicine authorised by Swissmedic under authorisation number 52815. The authorisation holder is Debiopharm Research & Manufacturing SA. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 14 January 1998 and the authorisation is valid without a time limit. ATC code L02AE04 places the medicine in the group Endocrine therapy.

  • Dispensing category A
  • Authorisation number 52815
  • ATC L02AE04
  • Synthetic medicines
Authorisation data
Authorisation number52815
NamePamorelin LA 3.75 mg
Full namePamorelin LA 3.75 mg, poudre et solvant pour suspension injectable à libération prolongée
Authorisation holderDebiopharm Research & Manufacturing SA
Medicinal product codeSynthetic medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeL02AE04
First authorisation14 January 1998
Authorisation validityunlimited
Strengths
No.NameDispensing categoryAuthorisation date
1Pamorelin LA 3.75 mg, poudre et solvant pour suspension injectable à libération prolongéeA14 January 1998
2Pamorelin LA 3.75 mg, poudre et solvant pour suspension injectable à libération prolongéeA07 September 2018

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
291SetL02AE0407.16.2.A
11SetL02AE0407.16.2.A

Scroll the table sideways

Medicines in the same ATC group

Other medicines from this authorisation holder

Frequently asked questions

Is Pamorelin LA 3.75 mg authorised in Switzerland?

Yes. Pamorelin LA 3.75 mg is authorised by Swissmedic under authorisation number 52815, data as of 01 September 2026. The authorisation is valid without a time limit.

Which dispensing category does Pamorelin LA 3.75 mg have?

Pamorelin LA 3.75 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Pamorelin LA 3.75 mg?

The authorisation holder is Debiopharm Research & Manufacturing SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com